
Pfizer Canada Announces EpiPen Shortage
A manufacturing disruption has led to an EpiPen shortage in Canada, which currently has no alternative auto-injectors available on the market.
In a Jan. 11, 2018 press statement, Pfizer Canada announced that it is experiencing a shortage of EpiPen auto-injectors in the 0.3 mg format.
EpiPen is used to deliver an emergency treatment of adrenaline (epinephrine) to patients who are at risk or have a history of life-threatening allergic reactions (anaphylaxis). According to Health Canada, the department responsible for Canadian public health, there are currently no alternative auto-injectors available on the market in Canada.
The shortage,
Additional limited inventory will be supplied at the beginning of February 2018, which will be placed under allocation, according to Pfizer. The company also stated that the shortage does not impact EpiPen Jr. (0.15 milligrams), which remain available.
This shortage is another event in a series of recent issues involving EpiPen. In
In
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.